ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative

Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet